Transforming and tumorigenic activity of JAK2 by fusion to BCR: Molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Cuesta Domínguez, Álvaro ^a   Ortega, Mara ^a   Ormazábal, Cristina ^b   Santos Roncero, Matilde ^a   Galán Díez, Marta ^a   Steegmann, Juan Luis ^a   Figuera, Ángela ^a   Arranz, Eva ^a   Vizmanos, José Luis ^b   Bueren, Juan A ^c   Río, Paula ^c   Fernández Ruiz, Elena ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BREAKPOINT CLUSTER REGION PROTEIN; CYCLOPHOSPHAMIDE; INTERLEUKIN 3; JANUS KINASE 2; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; STAT5 PROTEIN; BCL2L1 PROTEIN, HUMAN; BCL2L1 PROTEIN, MOUSE; BCR PROTEIN, HUMAN; BCR PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN BCL X;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BCL XL GENE; BCR JAK2 GENE; CARCINOGENESIS; CASE REPORT; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG POTENCY; EMBRYO; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; WHOLE BODY RADIATION; ANIMAL; CELL LINE; CELL STRAIN HEK293; METABOLISM; METHODOLOGY; MIDDLE AGED; NUDE MOUSE; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION;

MUS MUSCULUS;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CELL LINE; FEMALE; HEK293 CELLS; HUMANS; JANUS KINASE 2; MALE; MICE; MICE, NUDE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCR; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84857558600     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032451     Document Type: Article

References (55)

1. Hoelzer D, (1993) Acute lymphoblastic leukemia-progress in children, less in adults. N Engl J Med 329: 1343-1344.
2. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, et al. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409.
3. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
4. Levy DE, Darnell JE Jr, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
5. Sternberg DW, Gilliland DG, (2004) The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol 22: 361-371.
6. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309-1312.
7. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90: 2535-2540.
8. Reiter A, Walz C, Watmore A, Schoch C, Blau I, et al. (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65: 2662-2667.
9. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, et al. (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44: 329-333.
10. Lane SW, Fairbairn DJ, McCarthy C, Nandini A, Perry-Keene J, et al. (2008) Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol 142: 503.
11. Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, et al. (2008) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet 183: 105-108.
12. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC, (2008) Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 47: 884-889.
13. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, et al. (2009) Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23: 134-143.
14. Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, et al. (2011) JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 117: 4056-4064.
15. Tefferi A, Gilliland DG, (2007) Oncogenes in myeloproliferative disorders. Cell Cycle 6: 550-566.
16. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106: 9414-9418.
17. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, et al. (2010) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 107: 252-257.
18. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, et al. (2010) Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116: 4874-4884.
19. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, et al. (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21: 1658-1668.
20. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311-320.
21. Pardanani A, (2008) JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23-30.
22. Hitoshi Y, Lin N, Payan DG, Markovtsov V, (2010) The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol 91: 189-200.
23. van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, et al. (1995) Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 9: 329-335.
24. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
25. Rio P, Segovia JC, Hanenberg H, Casado JA, Martinez J, et al. (2002) In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood 100: 2032-2039.
26. Daley GQ, Baltimore D, (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 85: 9312-9316.
27. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, et al. (2000) Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95: 2076-2083.
28. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, et al. (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17: 5321-5333.
29. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, et al. (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 11: 1391-1397.
30. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, et al. (2001) The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 98: 3778-3783.
31. McLaughlin J, Chianese E, Witte ON, (1987) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 84: 6558-6562.
32. Broome HE, Dargan CM, Krajewski S, Reed JC, (1995) Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J Immunol 155: 2311-2317.
33. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF, (1999) Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 98: 181-191.
34. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, et al. (1999) Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274: 22165-22169.
35. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, et al. (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16: 1383-1390.
36. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984.
37. Yoshimura A, Ichihara M, Kinjyo I, Moriyama M, Copeland NG, et al. (1996) Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. Embo J 15: 1055-1063.
38. Basham B, Sathe M, Grein J, McClanahan T, D'Andrea A, et al. (2008) In vivo identification of novel STAT5 target genes. Nucleic Acids Res 36: 3802-3818.
39. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, et al. (2011) High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117: 3409-3420.
40. Ho JM, Beattie BK, Squire JA, Frank DA, Barber DL, (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93: 4354-4364.
41. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB, (1996) P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 56: 3426-3430.
42. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, et al. (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66: 11314-11322.
43. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, et al. (2004) Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 6: 395-404.
44. Prosch S, Stein J, Staak K, Liebenthal C, Volk HD, et al. (1996) Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 377: 195-201.
45. Daley GQ, Van Etten RA, Baltimore D, (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
46. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, et al. (2000) TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95: 3891-3899.
47. Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, et al. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20: 1094-1104.
48. McWhirter JR, Galasso DL, Wang JY, (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13: 7587-7595.
49. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, et al. (2006) Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 107: 4898-4906.
50. Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr, (2006) STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107: 4917-4925.
51. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, et al. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2: 98-110.
52. Million RP, Van Etten RA, (2000) The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96: 664-670.
53. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479-492.
54. Pallis M, Zhu YM, Russell NH, (1997) Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 11: 945-949.
55. Van Etten RA, (2001) Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models. Curr Opin Hematol 8: 224-230.